Welcome to our dedicated page for Protagenic Therapeutics news (Ticker: PTIX), a resource for investors and traders seeking the latest updates and insights on Protagenic Therapeutics stock.
Protagenic Therapeutics, Inc. (NASDAQ: PTIX) is a biopharmaceutical company developing neuro-active peptide and related therapeutics for stress-related and central nervous system (CNS) disorders. The PTIX news feed on Stock Titan highlights company announcements that explain how its clinical programs, business transactions, and listing status are evolving over time.
Investors following PTIX news can read detailed updates on the company’s lead peptide candidate, PT00114, including milestones in single ascending dose and multiple-dose Phase 1 studies in healthy volunteers. Recent press releases describe safety, tolerability, and pharmacokinetic findings for PT00114, as well as the company’s plans to use Phase 1 data to support advancement into Phase 2 studies in stress-related and mood disorders such as depression, anxiety, and PTSD.
News coverage also includes pipeline and corporate developments, such as the announced business combination with Phytanix Bio Inc. to form a combined entity called Phytanix, Inc. Company statements outline how this transaction adds preclinical CNS assets, including a potassium channel modulator, cannabinoid-based compounds with composition-of-matter IP, and modified stilbenoid candidates with anticonvulsant activity in preclinical models.
In addition, PTIX news items feature capital markets and regulatory updates, including private placements, warrant exercises, a 1-for-14 reverse stock split intended to address Nasdaq minimum bid price requirements, and Nasdaq notices related to continued listing standards and periodic filing timelines. Legal filings connected to the Phytanix share exchange agreement and other governance matters are also reported through current reports and press releases. By reviewing this news stream, readers can see how Protagenic describes the progress of its CNS-focused pipeline, its financing activities, and its efforts to manage exchange listing and regulatory obligations.
Protagenic Therapeutics has announced a 1-for-14 reverse stock split of its common stock, effective May 5, 2025. This strategic move aims to maintain Nasdaq compliance with minimum bid price requirements.
The split will reduce outstanding shares from approximately 8.2 million to 588,750. Trading will continue under the symbol PTIX with a new CUSIP number (74365N301). Key points include:
- Stockholder approval received on April 18, 2025, for a ratio range of 1-for-10 to 1-for-20
- Automatic conversion: 14 current shares will convert to 1 new share
- Fractional shares will be rounded up to the next whole share
- Proportionate adjustments will apply to exercise prices and equity awards
Equiniti Trust Company, the transfer agent, will handle the conversion process. Book-entry holders require no action, while certificate holders will receive instructions via mail for share conversion.
Protagenic Therapeutics (NASDAQ:PTIX) has closed a private placement raising $1.275 million in gross proceeds. The offering included 1,948,295 shares of common stock and two series of warrants. Each series includes 1,948,295 warrants with an exercise price of $0.64 per share. Series A warrants have an 18-month term, while Series B warrants extend for 5 years. The purchase price was set at $0.64 per share ($0.89 for insiders). The company plans to use the proceeds for working capital purposes. Brookline Capital Markets acted as the sole placement agent.
Protagenic Therapeutics (Nasdaq:PTIX) has announced a private placement offering to raise $1.275 million in gross proceeds. The company will issue 1,948,295 shares of common stock at $0.64 per share ($0.89 for insiders), along with series A and B warrants. The series A warrants have an 18-month term while series B warrants extend for 5 years, both with an exercise price of $0.64 per share. Brookline Capital Markets is serving as the sole placement agent. The offering is expected to close by November 4, 2024, with proceeds intended for working capital purposes.
Protagenic Therapeutics (NASDAQ: PTIX) announced promising safety results from the single dose portion of its Phase 1 trial for PT00114, a stress-regulating peptide. The trial involved 30 subjects across five cohorts who received doses up to 1,000 micrograms. No clinically-relevant adverse events were reported. PT00114 aims to address stress, a key factor in psychiatric disorders such as PTSD, depression, anxiety, addiction, and potentially obesity. The multiple dose portion of the trial will commence later this year. An investor call is scheduled for May 22, 2024, at 10:00 am ET to discuss these findings.
Protagenic Therapeutics, Inc. completes enrollment in the single dose portion of Phase 1 trial for PT00114, a synthetic stress-regulating peptide, showing outstanding tolerability. The trial aims to revolutionize treatment for neuropsychiatric disorders like anxiety, depression, PTSD, and addiction. Data from the safety trial phase are expected in May.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.